Symbiotec Pharmalab: Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement…
Symbiotec Pharmalab (SYMBIOTEC) filed a disclosure titled "Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical company for Dual Chamber Vial…". The company is valued…
What happened
Symbiotec Pharmalab (SYMBIOTEC) filed a disclosure with the exchanges on 30 September 2026 at 08:16 PM titled "Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical company for Dual Chamber Vial…".
Company snapshot
Symbiotec Pharmalab is a small-cap company, with a market value of about ₹7,561 crore.
The stock last traded at ₹1,176.8, against a 52-week range of ₹934.2–₹1,196.8 (1.7% below the high).
Promoters held 33.28% at the end of Q2 FY27. Foreign institutions owned 21.08% and domestic institutions 27.52%.
What history shows
BCEIE has no earlier approval filing from this company on record since May 2026.
Market-wide, 1,486 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
- SYMBIOTEC PHARMALAB LTD Share Price
- Symbiotec Pharmalab Receives U.S. FDA EIR With VAI Status For Pithampur Facility
- Symbiotec Pharmalab Jumps 7.5% After US FDA Plant Report
- Symbiotec Pharmalab Receives U.S. FDA Eir For Pithampur Facility With Vai Status
- Symbiotec Pharmalab Initiation: Can new growth engines unlock the next leg of growth?
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.